Presentation is loading. Please wait.

Presentation is loading. Please wait.

Product characteristics and pharmacokinetics of intranasal ipratropium bromide  Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret.

Similar presentations


Presentation on theme: "Product characteristics and pharmacokinetics of intranasal ipratropium bromide  Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret."— Presentation transcript:

1 Product characteristics and pharmacokinetics of intranasal ipratropium bromide 
Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret Wecker, PhDa, Thomas MacGregor, PhDa  Journal of Allergy and Clinical Immunology  Volume 95, Issue 5, Pages (May 1995) DOI: /S (95) Copyright © 1995 Mosby, Inc. Terms and Conditions

2 FIG. 1 Schematic representation of the chemical structures of ipratropium bromide and atropine. PC7.4 is the octanol-buffer partition coefficient at pH 7.4. Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

3 FIG. 2 Assessment protocol for pharmacokinetic of ipratropium bromide nasal spray (0.06%) with its saline vehicle in healthy volunteers and in the same subjects after infection with human rhinovirus 39. Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

4 FIG. 3 Pupillary measurements after administration of ipratropium bromide (0.03% and 0.06%) and its saline vehicle in healthy volunteers. Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

5 FIG. 3 Pupillary measurements after administration of ipratropium bromide (0.03% and 0.06%) and its saline vehicle in healthy volunteers. Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

6 FIG. 4 Comparison of pupillary measurements after administration of ipratropium bromide (0.06%) and its saline vehicle in healthy volunteers and in the same subjects after infection with rhinovirus 39 (days 3 and 7). Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

7 FIG. 4 Comparison of pupillary measurements after administration of ipratropium bromide (0.06%) and its saline vehicle in healthy volunteers and in the same subjects after infection with rhinovirus 39 (days 3 and 7). Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

8 FIG. 4 Comparison of pupillary measurements after administration of ipratropium bromide (0.06%) and its saline vehicle in healthy volunteers and in the same subjects after infection with rhinovirus 39 (days 3 and 7). Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions


Download ppt "Product characteristics and pharmacokinetics of intranasal ipratropium bromide  Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret."

Similar presentations


Ads by Google